Europe Today
AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
This story was reported by Europe News. EUROPES curates Europe's most relevant coverage — read the full report at the original source.
Read full coverage at Europe News →